March 29, 2018 / 12:02 PM / 23 days ago

BRIEF-Armo Biosciences Enrolls Patient In The Cypress 2 Trial Evaluating AM0010

Reuters Staff

1 Min Read

March 29 (Reuters) - Armo Biosciences Inc:

* ARMO BIOSCIENCES ENROLLS FIRST PATIENT IN THE CYPRESS 2 TRIAL EVALUATING AM0010 IN NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.